EMA Withdrawn: PegIntron (peginterferon alfa-2b) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA withdrew PegIntron (peginterferon alfa-2b) from the market for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Merck Sharp & Dohme B.V.. Decision date: 21/04/2021